At the time of writing, UroGen Pharma Ltd [URGN] stock is trading at $13.02, up 6.29%. An important factor to consider is whether the stock is rising or falling in short-term value. The URGN shares have gain 7.34% over the last week, with a monthly amount glided 4.33%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
UroGen Pharma Ltd [NASDAQ: URGN] stock has seen the most recent analyst activity on August 22, 2024, when Guggenheim initiated its Buy rating and assigned the stock a price target of $40. Previously, Jefferies downgraded its rating to Hold on February 08, 2023, and dropped its price target to $10. On April 27, 2022, Berenberg initiated with a Buy rating and assigned a price target of $20 on the stock. H.C. Wainwright reiterated its Buy rating and increased its price target to $57 on April 16, 2020. H.C. Wainwright reiterated its recommendation of a Buy and reduced its price target to $53 on April 13, 2020. National Securities started tracking with a Neutral rating for this stock on January 09, 2020, and assigned it a price target of $37. In a note dated May 30, 2019, JP Morgan initiated an Neutral rating.
For the past year, the stock price of UroGen Pharma Ltd fluctuated between $10.60 and $20.70. Currently, Wall Street analysts expect the stock to reach $38.6 within the next 12 months. UroGen Pharma Ltd [NASDAQ: URGN] shares were valued at $13.02 at the most recent close of the market. An investor can expect a potential return of 196.47% based on the average URGN price forecast.
Analyzing the URGN fundamentals
According to UroGen Pharma Ltd [NASDAQ:URGN], the company’s sales were 85.01M for trailing twelve months, which represents an 3.35% jump. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -0.94%, Pretax Profit Margin comes in at -1.29%, and Net Profit Margin reading is -1.34%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is 3.88 and Total Capital is -0.32. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of3.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.34 points at the first support level, and at 11.67 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.51, and for the 2nd resistance point, it is at 14.01.
Ratios To Look Out For
It is important to note that UroGen Pharma Ltd [NASDAQ:URGN] has a current ratio of 8.15. On the other hand, the Quick Ratio is 7.93, and the Cash Ratio is 6.45. Considering the valuation of this stock, the price to sales ratio is 6.45, the price to book ratio is 17.68.
Transactions by insiders
Recent insider trading involved Schoenberg Mark, Chief Medical Officer, that happened on Sep 09 ’24 when 859.0 shares were sold. General Counsel, Smith Jason Drew completed a deal on Sep 09 ’24 to sell 1521.0 shares. Meanwhile, Officer Schoenberg Mark bought 859.0 shares on Sep 09 ’24.
